Daiichi Sankyo will present over 45 abstracts showcasing new clinical research across its oncology portfolio at the 2024 ESMO Asia Congress, San Antonio Breast Cancer Symposium (SABCS), and American Society of Hematology (ASH) Annual Meeting. These presentations will precede the company’s Science & Technology Day and demonstrate advancements toward establishing new cancer care standards. Three late-breaking presentations are planned. At ESMO Asia, a pooled analysis of datopotamab deruxtecan (Dato-DXd) data from the TROPION-Lung05 and TROPION-Lung01 trials in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) will be presented. SABCS will feature a subgroup analysis from the DESTINY-Breast06 trial of ENHERTU (trastuzumab deruxtecan) in patients with unresectable or metastatic HR positive, HER2 low breast cancer. Also, at SABCS, the primary analysis from the VALENTINE trial of patritumab deruxtecan (HER3-DXd) in patients with early HR positive, HER2 negative breast cancer will be shared.
ESMO Asia will highlight innovation in lung, breast, gastric, and biliary tract cancers. A pooled analysis of Dato-DXd in previously treated EGFR-mutated advanced NSCLC from the TROPION-Lung05 and TROPION-Lung01 trials will be a key presentation. Mini oral presentations will cover the TROPION-Breast01 trial of Dato-DXd in Chinese patients with previously treated metastatic HR positive, HER2 low or negative breast cancer, and final results from the DESTINY-Gastric06 trial of ENHERTU in Chinese patients with previously treated HER2 positive advanced gastric or gastroesophageal junction adenocarcinoma. The DESTINY-Gastric06 results supported the recent conditional approval of ENHERTU in China for this indication. Trials-in-progress posters will detail the designs of ongoing ENHERTU trials, including DESTINY-BTC01 (ENHERTU with rilvegostomig versus standard of care in previously untreated HER2 expressing biliary tract cancer) and DESTINY-Gastric03 (ENHERTU with rilvegostomig and chemotherapy in HER2 positive or HER2 low gastric or GEJ adenocarcinoma). An update on the DESTINY-PanTumor02 trial of ENHERTU will also be presented, showcasing five new cohorts enrolling patients with various HER2 expressing solid tumors.
SABCS will feature continued progress in breast cancer research. A subgroup analysis of DESTINY-Breast06 will explore the impact of prior endocrine-based therapy response on outcomes in patients with HR positive, HER2 low breast cancer treated with ENHERTU versus chemotherapy. Primary results from the VALENTINE trial evaluating neoadjuvant HER3-DXd, alone or with letrozole, in high-risk HR positive, HER2 negative early breast cancer will also be presented. Additional data includes biomarker analyses from DESTINY-Breast03, health-related quality of life data from DESTINY-Breast12, and final results from the DESTINY-Breast08 dose expansion. Trial-in-progress posters will detail studies evaluating ENHERTU in combination with valemetostat in previously treated HER2 low breast cancer.
At ASH, various sub-analyses of the QuANTUM-First trial of VANFLYTA (quizartinib) in newly diagnosed FLT3-ITD positive AML will be shared. An oral presentation will focus on co-mutations and their impact on remission, survival, and relapse. Posters will address the impact of continuation therapy, FLT3-ITD mutation detection assays, and a comparison of VANFLYTA to midostaurin. Data from the QUIWI trial, which evaluated VANFLYTA in combination with chemotherapy in newly diagnosed FLT3-ITD negative AML, will also be presented, including final results and sub-analyses. The QuANTUM-Wild trial design, based on QUIWI, will be featured. Finally, primary results from the VALYM trial of valemetostat in relapsed or refractory large B-cell lymphoma and an analysis of circulating tumor DNA from the VALENTINE-PTCL01 trial in relapsed or refractory peripheral T-cell lymphoma will be presented. Daiichi Sankyo’s Science & Technology Day on December 16, 2024, will provide further overview and updates on R&D strategy.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
